Extensive research programs—including the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) [10], Peptide Innovation for Early Diabetes Treatment (PIONEER) [11], and Semaglutide Treatment Effect in People with Obesity (STEP) [12] trials—have highlighted its superiority in glycemic control and weight reduction compared with other GLP-1R agonists and anti-obesity medications [7,13]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.